Karista

Karista has spent more than two decades quietly becoming one of France’s most experienced specialist investors in healthcare and deeptech innovation. Founded in 2001 in Paris and rebranded from CapDecisif Management, Karista has funded more than ninety companies across health, digital, deeptech, and what the firm calls NewSpace, with health investments running across biotech and biopharma, MedTech, and digital health. With check sizes of one to five million dollars across Seed, Series A, and Series B, Karista occupies the early-stage seat that most matters for European clinical AI and healthtech founders: the round where capital alone is insufficient and an investor’s clinical fluency, regulatory understanding, and operating network determine whether the company gets to Series B at all.

The investment thesis is genuinely cross-disciplinary within healthcare. Karista invests across the spectrum from biotech and biopharma through MedTech to digital health, with a particular focus on companies making healthcare smarter through data, improving clinical outcomes, or reinventing the patient journey. The firm’s two decades of healthcare investing have produced both depth in clinical and regulatory diligence and breadth across therapeutic areas. AI is treated as a substrate rather than a thesis; the firm backs AI-enabled diagnostics, clinical decision support, surgical guidance, and digital therapeutics where the underlying clinical or scientific case is sound. Founders should expect technical and clinical diligence calibrated to the maturity of the asset, with biotech investments examined for translational science and digital health investments examined for clinical workflow integration. The firm’s posture is that healthcare investing requires patience and that early-stage capital should be sized to the next clinical or regulatory milestone, not to a generic eighteen-month plan.

The portfolio reads as a careful map of European healthcare innovation. Deemea has built a software suite for structuring and exploiting medical imaging data for clinical research, illustrating Karista’s interest in clinical data infrastructure. SamanTree Medical has developed the Histolog Scanner, a breakthrough innovation for verifying complete tumor removal during surgery, an example of the firm’s MedTech franchise. Ludocare strengthens young patients’ education and adherence to treatment with a remote monitoring companion robot. Kranus Health is a global provider of men’s health prescription digital therapeutics, showing the firm’s appetite for digital therapeutics with regulatory clearance. Across more than ninety portfolio companies over two decades, Karista’s track record includes eight IPOs and twenty-three acquisitions, with notable outcomes in adjacent sectors including Navya Technology, Theraclion, and Sequans.

Stage and check size make Karista a meaningful early-stage partner. One-to-five-million-dollar checks at Seed, Series A, and Series B fit naturally as either lead positions in smaller rounds or significant participation in larger rounds led by other investors. The firm typically takes board seats commensurate with its position, reserves capital for follow-on within the portfolio, and supports companies through multiple rounds when the thesis holds. Pure scale-stage growth companies are not the audience; the firm engages most strongly with companies at the inflection between scientific or clinical proof and early commercial traction. The recent Eutelsat partnership in 2023 reflects the firm’s growing engagement in cross-sector deeptech, but health remains a core franchise.

Decision-making sits with a senior team in Paris that has been investing in French and European healthcare for the better part of two decades. Key partners include Alain Gavin, Amine Benmoussa, and Baudouin Hue, among others, who bring operational and investment experience across the firm’s sectors. Diligence is thorough, with healthcare investments engaging clinical and regulatory advisors and connecting with the firm’s network of academic and industrial partners across France.

Warm-intro paths run through existing Karista portfolio CEOs, leading French and European Seed funds whose Series A graduates are Karista’s natural pipeline, French academic medical centers and research institutions including the major CHUs and university hospitals, and the firm’s network of operating partners across health and deeptech. Investment bankers and corporate development teams in pharma and devices with French operations occasionally route deals to the firm. Cold inbound through generic forms is the slowest path; founders who arrive with clinical advisors and credible references move materially faster through diligence.

Founders should approach Karista when they have a defined clinical or regulatory plan, identified development partners, and a credible answer to who the first clinical site or first commercial customer will be. Pure software stories without clinical workflow integration may find better-aligned generalist partners elsewhere. The firm rewards founders who treat clinical and regulatory rigor as a competency, who arrive with named advisors and references, and who size their early rounds to specific clinical milestones rather than generic time horizons. For European healthcare AI and digital health founders at Seed through Series B, Karista is among the most experienced specialist partners on the continent.